|
1 |
Effektivität, Immunogenität und Sicherheit eines Re-switches von Biosimilar SB2 auf Originator Infliximab bei Patienten mit chronisch entzündlichen Darmerkrankungen: 12-Monats-Daten einer prospektiven Beobachtungsstudie
Donhauser, Moritz. - Erlangen : Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 2025
|
|
|
2 |
A Cost-Effectiveness Analysis of Gonadotropins Used for Ovarian Stimulation during Assisted Reproductive Technology Based on Data from the French Nationwide Claims Database (SNDS)
Enthalten in Gynecologic and obstetric investigation Bd. 90, 2025, Nr. 3: 211-225. 15 S.
|
|
|
|
3 |
Effects of Generic Entry on Market Shares and Prices of Originator Drugs: Evidence from Chinese Pharmaceutical Market
Enthalten in PharmacoEconomics - open 19.3.2025: 1-10
|
|
|
|
4 |
The annual update GLODAPv2.2023: the global interior ocean biogeochemical data product
Enthalten in Earth system science data Bd. 16, 2024, Nr. 4: 2047-2072. 26 S.
|
|
|
|
5 |
Conjugation of Polycationic Peptides Extends the Efficacy Spectrum of β‐Lactam Antibiotics
Enthalten in Advanced science 05.11.2024. 12 S.
|
|
|
|
6 |
Real-World Comparative Analysis of Trastuzumab Originator and Biosimilars: Safety, Efficacy, and Cost Effectiveness
Enthalten in BioDrugs 16.10.2024: 1-12
|
|
|
|
7 |
Clinical Utilization of Generic Drugs and Biosimilars for Ulcerative Colitis Treatment: Insights from a Nationwide Database Study in Japan
Enthalten in Inflammatory intestinal diseases Bd. 9, 2024, Nr. 1: 29-39. 11 S.
|
|
|
|
8 |
Switching from adalimumab originator to biosimilar in patients with hidradenitis suppurativa results in losses of response — data from the German HS registry HSBest
Kirsten, Natalia. - Würzburg : Universität Würzburg, 2023
|
|
|
|
9 |
Effektivität und Sicherheit nach einem Switch vom Originator Infliximab auf das Biosimilar SB2 bei CED-Patienten: 24-Monatsdaten einer prospektiven Kohortenstudie
Cohnen, Sarah. - Erlangen : Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 2022
|
|
|
|
10 |
Re-exposure with a TNF inhibitor bio-similar was well tolerated and led to sustained control of psoriatic arthritis after allergic reaction to the TNF inhibitor bio-originator
Valor-Méndez, Larissa. - Erlangen : Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 2022
|
|
Administration
